Neglected Diseases and Drug Discovery (inbunden)
Fler böcker inom
Inbunden (Hardback)
Antal sidor
Royal Society of Chemistry
Campbell, Simon (contributions)/Mitton-Fry, Mark (contributions)/Gutteridge, Win (contributions)/Vennerstrom, Jonathan (contributions)/Phillips, Meg (contributions)/Chatterjee, Arnab (contributions)/Burrows, Jeremy N (contributions)/Croft, Simon (contributions)/Jacobs, Bob (contributions)/Overington
241 x 162 x 29 mm
822 g
Antal komponenter

Neglected Diseases and Drug Discovery

Inbunden,  Engelska, 2011-11-04
  • Skickas från oss inom 5-8 vardagar.
  • Fri frakt över 249 kr för privatkunder i Sverige.
Finns även som
Visa alla 1 format & utgåvor
There are about 8 million deaths each year from neglected tropical diseases (NTDs) in the underdeveloped world, whilst drug discovery focus and practice is only recently taking on greater urgency and embracing the latest technologies. This unique book is a state of the art review of drug discovery in respect of NTDs and highlights best practice to guide the ongoing drug discovery effort and also to raise debate and awareness in areas that remain highly neglected. All the major diseases such as malaria, trypanosomatids and TB are covered, with a review of each disease and established compounds, new mechanistic classes and new horizons. Each chapter highlights the key science that has led to breakthroughs, with detailed assessment of the key medicinal chemistry involved, and critical appraisal of new emerging approaches. Later chapters highlight under publicized disease areas where the medical needs are neglected and research is very limited, to raise awareness. The editors, acknowledged experts in the field, have a wealth of experience in successful drug discovery practice and tropical diseases.
Visa hela texten

Passar bra ihop

  1. Neglected Diseases and Drug Discovery
  2. +
  3. Co-Intelligence

De som köpt den här boken har ofta också köpt Co-Intelligence av Ethan Mollick (häftad).

Köp båda 2 för 2079 kr


Har du läst boken? Sätt ditt betyg »

Fler böcker av författarna

  • Orphan Drugs and Rare Diseases

    David C Pryde, Michael J Palmer

    Orphan drugs are designated drug substances that are intended to treat rare or 'orphan' diseases. More than 7000 rare diseases are known that collectively affect some 6-7% of the developed world's population; however, individually, any single, rar...

  • Chemokine Protocols

    Amanda E I Proudfoot, Timothy N C Wells, Christine Power

    The chemokines family of small proteins are involved in numerous b- logical processes ranging from hematopoiesis, angiogenesis, and basal l- kocyte trafficking to the extravasation and tissue infiltration of leukocytes in response to inflammatory ...

Recensioner i media

"fascinating and sobering reading." "an essential purchase for those researching Tropical disease controls." "It Is comprehensive, timely and well referenced" -- John Mann * Chemistry and Industry * "This is a very timely and valuable review of drug discovery for neglected (tropical) diseases." -- Prof. Ian Gilbert, University of Dundee (UK) * ChemMedChem 2012, 7, 1858 1862 * "The book would be very useful for all those involved in drug discovery for neglected diseases. It will quickly bring scientists moving into neglected disease discovery up to speed in the area, and it is also a very good introduction for Ph.D. students." -- Prof. Ian Gilbert, University of Dundee (UK) * ChemMedChem 2012, 7, 1858 1862 *

Övrig information

Michael J Palmer is a Senior Principal Scientist at Pfizer. He has worldwide medicinal chemistry and drug discovery based experience across many different therapeutic areas. He is a member of the drug discovery teams responsible for carduraTM, additional cardiovascular agents that progressed to man, and cardiovascular and antiviral agents in Phase I and II stages of development. Timothy NC Wells is Chief Scientific Officer at Medicines for Malaria Venture, Geneva, Switzerland.


Malaria; Trypanosomatids; TB; Flavivirus based diseases (Dengue fever, Yellow fever, West Nile virus); Helminth, nematode and schistosoma based diseases; HIV Lower respiratory tract infection; Diarrhea